Trial Profile
A Real-world study to evaluate eribulin use as second and third line of chemotherapy in patients with metastatic Breast cancer from ESME database
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Antineoplastics
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 15 Dec 2019 Results, a sub-analysis assessing imbalance for HER2+ tumors and concomitant anti-HER2 targeted therapies use, published in the International Journal of Cancer
- 11 Jan 2018 New trial record
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium